Investigational therapeutics for the treatment of progressive supranuclear palsy

References

• Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;64(10):333–359.
   Google Scholar
• Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140(2):99–119.
   PubMedGoogle Scholar
• Goedert M, Spillantini MG, Cairns NJ, et al. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8(1):159–168.
   PubMed Web of Science ®Google Scholar
• Dickson DW, Kouri N, Murray ME, et al. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-Tau). J Mol Neurosci. 2011;45(3):384–389.
   PubMed Web of Science ®Google Scholar
• ITS C-G, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86(18):1736–1743.
   PubMedGoogle Scholar
• Takigawa H, Ikeuchi T, Aiba I, et al. Japanese Longitudinal Biomarker Study in PSP and CBD (JALPAC): a prospective multicenter PSP/CBD cohort study in Japan. Parkinsonism Relat Disord. 2016;22:e120–e121.
   Google Scholar
• Respondek G, Kurz C, Arzberger T, et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord. 2017;32(7):995–1005.
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2022 May 19;32(6):853–864.
   Google Scholar
• Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996Jul01;47:1–9.
   Google Scholar
• Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain. 2005 Mar 25;128(6):1247–1258.
   PubMedGoogle Scholar
• Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66(1):41–48.
   PubMed Web of Science ®Google Scholar
• Koga S, Josephs KA, Ogaki K, et al. Cerebellar ataxia in progressive supranuclear palsy: an autopsy study of PSP‐C. Mov Disord. 2016;31(5):653–662.
   PubMed Web of Science ®Google Scholar
• Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014 Nov 06;29(14):1758–1766.
   PubMed Web of Science ®Google Scholar
• Shoeibi A, Litvan I, Tolosa E, et al. Progression of two progressive supranuclear palsy phenotypes with comparable initial disability. In: Parkinsonism relat disord. 2019. DOI:https://doi.org/10.1016/j.parkreldis.2019.07.010.
   Google Scholar
• Caparros-Lefebvre D, Golbe LI, Deramecourt V, et al. A geographical cluster of progressive supranuclear palsy in northern France. Neurology. 2015 Sep 12;85(15):1293–1300.
   PubMed Web of Science ®Google Scholar
• Litvan I, Proudfoot JA, Martin ER, et al. Gene-environment interactions in progressive supranuclear palsy.Front Neurol. 2022 Mar 9;12(1):664796.
   Google Scholar
• Litvan I, Lees PS, Cunningham CR, et al. Environmental and occupational risk factors for progressive supranuclear palsy: case-control study. Mov Disord. 2016Feb09 31(5):644–652.
   PubMed Web of Science ®Google Scholar
• Wray S, Saxton M, Anderton BH, et al. Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N‐terminally cleaved tau containing four microtubule‐binding repeats. J Neurochem. 2008;105(6):2343–2352.
   PubMed Web of Science ®Google Scholar
• Irwin DJ, Cohen TJ, Grossman M, et al. Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies. Brain. 2012;135(3):807–818.
   PubMedGoogle Scholar
• Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. Nat. 2021;598(7880):359–363. .
   Google Scholar
• Scheres SH, Zhang W, Falcon B, et al. Cryo-EM structures of tau filaments. Curr Opin Struct Biol. 2020;64:17–25.
   PubMedGoogle Scholar
• Massey LA, Micallef C, Paviour DC, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2012;27(14):1754–1762.
   PubMed Web of Science ®Google Scholar
• Massey LA, Jager HR, Paviour DC, et al. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology. 2013;80(20):1856–1861.
   PubMed Web of Science ®Google Scholar
• Quattrone A, Morelli M, Nigro S, et al. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson’s disease. Parkinsonism Relat Disord. 2018;54:3–8.
   PubMed Web of Science ®Google Scholar
• Quattrone A, Morelli M, Quattrone A, et al. Magnetic resonance parkinsonism index for evaluating disease progression rate in progressive supranuclear palsy: a longitudinal 2-year study. Parkinsonism Relat Disord. 2020;72:1–6.
   PubMed Web of Science ®Google Scholar
• Morelli M, Arabia G, Novellino F, et al. MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study. Neurology. 2011;77(11):1042–1047.
   PubMed Web of Science ®Google Scholar
• Quattrone A, Antonini A, Vaillancourt DE, et al. A new MRI measure to early differentiate progressive supranuclear palsy from de novo Parkinson’s disease in clinical practice: an international study. Mov Disord. 2021;36(3):681–689.
   PubMedGoogle Scholar
• Planetta PJ, Ofori E, Pasternak O, et al. Free-water imaging in Parkinson’s disease and atypical parkinsonism. Brain. 2016;139(2):495.
   PubMedGoogle Scholar
• Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology. 2013;80(9):857.
   PubMed Web of Science ®Google Scholar
• Villemagne VL, Fodero-Tavoletti MT, Masters CL, et al. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114–124.
   PubMed Web of Science ®Google Scholar
• Marquié M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787–800.
   PubMed Web of Science ®Google Scholar
• Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58.
   PubMedGoogle Scholar
• Cho H, Choi JY, Hwang MS, et al. Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord. 2016;2017(32):134–140.
   Google Scholar
• Hsu JL, Chen SH, Hsiao IT, et al. 18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty. Sci Reports101. 2020;10(1):1–10.
   PubMed Web of Science ®Google Scholar
• Ishiki A, Harada R, Okamura N, et al. Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy. Eur J Neurol. 2016;24(1):130–136.
   PubMedGoogle Scholar
• Tagai K, Ono M, Kubota M, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies. Neuron. 2021;109(1):42–58.e8.
   PubMedGoogle Scholar
• Tezuka T, Takahata K, Seki M, et al. Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Commun. 2021;3(4).42–58.e8
   Google Scholar
• Messerschmidt K, Barthel H, Brendel M, et al. 18 F-PI-2620 tau PET improves the imaging diagnosis of progressive supranuclear palsy. J Nucl Med. 2022;
   PubMedGoogle Scholar
• Chouliaras L, Thomas A, Malpetti M, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2022;1.
   Google Scholar
• Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(1):1.
   PubMedGoogle Scholar
• Sako W, Murakami N, Izumi Y and Kaji R. (2015). Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis. Journal of the Neurological Sciences, 352(1–2), 84–87. https://doi.org/10.1016/j.jns.2015.03.041
   PubMed Web of Science ®Google Scholar
• Rojas JC, Karydas A, Bang J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3(3):216–225.
   PubMed Web of Science ®Google Scholar
• Groveman BR, Orrù CD, Hughson AG, et al. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathol Commun. 2018;6(1):7.
   PubMedGoogle Scholar
• Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT -Qu IC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812–818.
   PubMed Web of Science ®Google Scholar
• Kraus A, Saijo E, Metrick MA, Metrick 2nd MA, et al. Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. Acta Neuropathol. 2018;137(4):585–598
   PubMedGoogle Scholar
• Saijo E, Metrick MA, Koga S, et al., 4-repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 139(1): 63–77. 2020. .
   PubMed Web of Science ®Google Scholar
• Buée L, Bussière T, Buée-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev. 2000;33(1):95–130.
   PubMed Web of Science ®Google Scholar
• Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer’s disease, Pick’s disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 2002;104(6):583–591.
   PubMed Web of Science ®Google Scholar
• Long ZM, Zhao L, Jiang R, et al. Valproic acid modifies synaptic structure and accelerates neurite outgrowth via the glycogen synthase kinase-3beta signaling pathway in an Alzheimer’s disease model. CNS Neurosci Ther. 2015;21(11):887–897.
   PubMed Web of Science ®Google Scholar
• Nakashima H, Ishihara T, Suguimoto P, et al. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. 2005;110(6):547–556.
   PubMedGoogle Scholar
• Leclair-Visonneau L, Rouaud T, Debilly B, et al. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg. 2016;146:35–39.
   PubMed Web of Science ®Google Scholar
• Hampel H, Ewers M, Burger K, et al. Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009;70(6):922–931.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470–478.
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Huppertz HJ, Wagenpfeil S, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord. 2014;29(4):479–487.
   PubMed Web of Science ®Google Scholar
• VandeVrede L, Dale ML, Fields S, et al. Open-label phase 1 futility studies of salsalate and young plasma in progressive supranuclear palsy. Mov Disord Clin Pract. 2020;7(4):440–447.
   PubMedGoogle Scholar
• Yuzwa S A, Shan X, Macauley M S, Clark T, Skorobogatko Y, Vosseller K and Vocadlo D J. (2012). Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol, 8(4), 393–399. https://doi.org/10.1038/nchembio.797
   PubMed Web of Science ®Google Scholar
• Cantuti-Castelvetri I, Keller-McGandy CE, Albers DS, et al. Expression and activity of antioxidants in the brain in progressive supranuclear palsy. Brain Res. 2002;930(1–2):170–181.
   PubMedGoogle Scholar
• Martinelli P, Scaglione C, Lodi R, et al. Deficit of brain and skeletal muscle bioenergetics in progressive supranuclear palsy shown in vivo by phosphorus magnetic resonance spectroscopy. Mov Disord. 2000;15(5):889–893.
   PubMed Web of Science ®Google Scholar
• Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q 10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23(7):942–949.
   PubMed Web of Science ®Google Scholar
• Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e266.
   PubMed Web of Science ®Google Scholar
• Nuebling G, Hensler M, Paul S, et al. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol. 2016;263(8):1565–1574.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2008;132(1):156–171.
   PubMedGoogle Scholar
• Neumann M, Kwong LK, Lee EB, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117(2):137–149.
   PubMed Web of Science ®Google Scholar
• Minami SS, Min SW, Krabbe G, et al. Progranulin protects against amyloid β deposition and toxicity in Alzheimer’s disease mouse models. Nat Med. 2014;20(10):1157.
   PubMedGoogle Scholar
• Callizot N, Estrella C, Burlet S, et al. AZP2006, a new promising treatment for Alzheimer’s and related diseases. Sci Rep. 2022;11:1–17.
   PubMedGoogle Scholar
• Magen I, Ostritsky R, Richter F, et al. Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein. Pharmacol Res Perspect. 2014;2(5):e00065.
   PubMedGoogle Scholar
• Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676–685.
   PubMed Web of Science ®Google Scholar
• Stamelou M, Schöpe J, Wagenpfeil S, et al. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Mov Disord. 2016;31(5):742.
   PubMedGoogle Scholar
• Zumbar CT, Usubalieva A, King PD, et al. The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells. J Neurooncol. 2018;137(3):481.
   PubMed Web of Science ®Google Scholar
• McQuade JL, Posada LP, Lecagoonporn S, et al. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res. 2016;26(6):604.
   PubMed Web of Science ®Google Scholar
• Boxer A, Tsai R, Koestler M, et al. A phase 1b, randomized, double-blind, placebo-controlled, sequential cohort, dose-ranging study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of tpi 287 (abeotaxane) in patients with prim. J Prev Alzheimers Dis. 2017;4:282–428.
   Google Scholar
• Zhang B, Carroll J, Trojanowski JQ, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012;32(11):3601–3611.
   PubMed Web of Science ®Google Scholar
• Beer T M, Higano C S, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L and Hannah A L. (2007). Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs, 25(6), 565–570. https://doi.org/10.1007/s10637-007-9068-1
   PubMed Web of Science ®Google Scholar
• Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease. J Alzheimer’s Dis. 2015;44(2):705–720.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet (London, England. 2016;388:2873.
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Cooper J, Murray TK, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 2014;127(5):667–683.
   PubMedGoogle Scholar
• Peeraer E, Bottelbergs A, Van Kolen K, et al. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol Dis. 2015;73:83–95.
   PubMedGoogle Scholar
• Clavaguera F, Hench J, Lavenir I, et al. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 2014;127(2):299–301.
   PubMedGoogle Scholar
• Kfoury N, Holmes BB, Jiang H, et al. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem. 2012;287(23):19440–19451.
   PubMed Web of Science ®Google Scholar
• Lee S-J, Desplats P, Sigurdson C, et al. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol. 2010;6(12):702.
   PubMed Web of Science ®Google Scholar
• Bi M, Ittner A, Ke YD, et al. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 2011;6(12):e26860.
   PubMedGoogle Scholar
• Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol. 2013;248:451–456.
   PubMedGoogle Scholar
• Selenica M-LB, Davtyan H, Housley SB, et al. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflammation. 2014;11(1):152.
   PubMedGoogle Scholar
• Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018;14(7):399.
   PubMed Web of Science ®Google Scholar
• Qureshi IA, Tirucherai G, Ahlijanian MK, et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimer’s Dement Transl Res Clin Interv. 2018;4(1):746–755.
   PubMedGoogle Scholar
• Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019;18(6):549–558.
   PubMed Web of Science ®Google Scholar
• Budur K, West T, Braunstein JB, et al. Results of a phase 1, single ascending dose, placebo-controlled study of ABBV-8E12 in patients with progressive supranuclear palsy and phase 2 study design in early Alzheimer’s disease. Alzheimer’s Dement J Alzheimer’s Assoc. 2017;13:599–600.
   Google Scholar
• Dam T et al. (2021). Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med, 27(8), 1451–1457. https://doi.org/10.1038/s41591-021-01455-x
   PubMed Web of Science ®Google Scholar
• West T, Hu Y, Verghese PB, et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies. J Prev Alzheimers Dis. 2017;4(4):236–241.
   PubMed Web of Science ®Google Scholar
• Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2016 [Dec 14];16(2):123–134.
   PubMedGoogle Scholar
• Walls KC, Ager RR, Vasilevko V, et al. p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci Lett. 2014;575:96–100.
   PubMed Web of Science ®Google Scholar
• Collin L, Bohrmann B, Göpfert U, et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease. Brain. 2014;137(10):2834–2846.
   PubMed Web of Science ®Google Scholar
• Mead BP, Kim N, Miller GW, et al. Novel focused ultrasound gene therapy approach noninvasively restores dopaminergic neuron function in a Rat Parkinson’s disease model. Nano Lett. 2017 [May 17];17(6):3533–3542.
   PubMed Web of Science ®Google Scholar
• Alecou T, Giannakou M, Damianou C. Amyloid beta plaque reduction with antibodies crossing the blood-brain barrier, which was opened in 3 sessions of focused ultrasound in a rabbit model.J Ultrasound Med. 2017;36(11):2257–2270.
   PubMedGoogle Scholar
• Igawa T, Tsunoda H, Kuramochi T, et al. Engineering the variable region of therapeutic IgG antibodies. MAbs. 2011;3(3):243–252.
   PubMed Web of Science ®Google Scholar
• Gentry EG, Henderson BW, Arrant AE, et al. Rho kinase inhibition as a therapeutic for progressive supranuclear palsy and corticobasal degeneration. J Neurosci. 2016;36(4):1316.
   PubMed Web of Science ®Google Scholar
• Bakhoum MF, Bakhoum CY, Ding Z, et al. Evidence for autophagic gridlock in aging and neurodegeneration. Transl Res. 2014;164(1):1–12.
   PubMedGoogle Scholar
• Poorkaj P, Muma NA, Zhukareva V, et al. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol. 2002;52(4):511–516.
   PubMedGoogle Scholar
• Park HK, Chung SJ. New perspective on parkinsonism in frontotemporal lobar degeneration. J Mov Disord Internet. 20136(1):1.
   PubMedGoogle Scholar
• Kaat LD, Boon AJW, Azmani A, et al. Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology. 2009;73(2):98–105.
   PubMedGoogle Scholar
• Fujioka S, Sanchez Contreras MY, Strongosky AJ, et al. Three sib-pairs of autopsy-confirmed progressive supranuclear palsy. Parkinsonism Relat Disord. 2015;21(2):101.
   PubMed Web of Science ®Google Scholar
• Im SY, Kim YE, Kim YJ. Genetics of progressive supranuclear palsy. J Mov Disord. 2015;8(3):122.
   PubMedGoogle Scholar
• Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet. 2005;14(21):3281–3292.
   PubMedGoogle Scholar
• Heckman MG, Kasanuki K, Brennan RR, et al. Association of MAPT H1 subhaplotypes with neuropathology of Lewy body disease. Mov Disord. 2019;34(9):1325–1332.
   PubMedGoogle Scholar
• Pastor P, Ezquerra M, Perez JC, et al. Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. Ann Neurol. 2004;56(2):249–258.
   PubMedGoogle Scholar
• Dawson HN, Ferreira A, V EM, et al. Inhibition of neuronal maturation in primary hippocampal neurons from τ deficient mice. J Cell Sci. 2001;114(6):1179–1187.
   PubMedGoogle Scholar
• Morris M, Hamto P, Adame A, et al. Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Neurobiol Aging. 2013;34(6):1523–1529.
   PubMedGoogle Scholar
• Lei P, Ayton S, Finkelstein DI, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012;18(2):291–295.
   PubMed Web of Science ®Google Scholar
• Ma QL, Zuo X, Yang F, et al. Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris water maze with aging. J Neurosci. 2014;34(21):7124–7136.
   PubMedGoogle Scholar
• Peacey E, Rodriguez L, Liu Y, et al. Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing. Nucleic Acids Res. 2012;40(19):9836–9849.
   PubMedGoogle Scholar
• DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481.
   PubMed Web of Science ®Google Scholar
• Xu H, W Rosler T, Carlsson T, et al. Tau silencing by siRNA in the P301S mouse model of tauopathy. Curr Gene Ther. 2014;14(5):343–351.
   PubMedGoogle Scholar
• Darras BT, Farrar MA, Mercuri E, et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs. 2019;33(9):919–932.
   PubMed Web of Science ®Google Scholar
• Grondin R, Kaytor MD, Ai Y, et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain. 2012;135(4):1197–1209.
   PubMedGoogle Scholar
• Franich NR, Fitzsimons HL, Fong DM, et al. AAV vector–mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington’s disease. Mol Ther. 2008;16(5):947–956.
   PubMed Web of Science ®Google Scholar
• Gomes MJ, Dreier J, Brewer J, et al. A new approach for a blood-brain barrier model based on phospholipid vesicles: membrane development and siRNA-loaded nanoparticles permeability. J Memb Sci. 2016;503:8–15.
   Google Scholar
• Gao X, Qian J, Zheng S, et al. Overcoming the blood-brain barrier for delivering drugs into the brain by using adenosine receptor nanoagonist. ACS Nano. 2014;8(4):3678–3689.
   PubMed Web of Science ®Google Scholar
• Bluett B, Pantelyat AY, Litvan I, et al. Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: a consensus statement of the curepsp centers of care. Front Neurol. 2021;12: 694872.
   PubMedGoogle Scholar
• Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy.Clin Neuropharmacol. 1993;16(4):338–346.
   PubMedGoogle Scholar
• Lang AE. Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord Off J Mov Disord Soc. 2005;20(S12):S83–S91.
   PubMedGoogle Scholar
• Litvan I, Bhatia KP, Burn DJ, et al. Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord Off J Mov Disord Soc. 2003;18(5):467–486.
   PubMed Web of Science ®Google Scholar
• Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996;60(6):615–620.
   PubMed Web of Science ®Google Scholar
• Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993;16(4):338–346.
   PubMedGoogle Scholar
• Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 1983;13:273–278.
   PubMed Web of Science ®Google Scholar
• Rajrut AH, Uitti RJ, Fenton ME, et al. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 1997;3(4):211–214.
   PubMedGoogle Scholar
• Aldrich MS, Foster NL, White RF, et al. Sleep abnormalities in progressive supranuclear palsy. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 1989;25:577–581.
   PubMedGoogle Scholar
• Radicati FG, Martinez Martin P, Fossati C, et al. Non motor symptoms in progressive supranuclear palsy: prevalence and severity. NPJ Park Dis. 2017;3(1):35.
   PubMedGoogle Scholar
• Kompoliti K, Goetz CG, Litvan I, et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998;55(8):1099–1102.
   PubMedGoogle Scholar
• Engel PA. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc. 1996;44(9):1072–1074.
   PubMedGoogle Scholar
• Müller J, Wenning GK, Wissel J, et al. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol. 2002;249(3):300–304.
   PubMedGoogle Scholar
• Polo KB, Jabbari B. Botulinum toxin‐A improves the rigidity of progressive supranuclear palsy. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 1994;35:237–239.
   PubMed Web of Science ®Google Scholar
• Pattee GL, Wymer JP, Lomen-Hoerth C, et al. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Curr Med Res Opin. 2014;30(11):2255–2265.
   PubMed Web of Science ®Google Scholar
• Clerici I, Ferrazzoli D, Maestri R, et al. Rehabilitation in progressive supranuclear palsy: effectiveness of two multidisciplinary treatments. PLoS One. 2017;12(2):e0170927.
   PubMed Web of Science ®Google Scholar
• Wiblin L, Lee M, Burn D. Palliative care and its emerging role in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 2017;34:7–14.
   PubMedGoogle Scholar
• Zampieri C, Di Fabio RP. Balance and eye movement training to improve gait in people with progressive supranuclear palsy: quasi-randomized clinical trial. Phys Ther. 2008;88(12):1460–1473.
   PubMed Web of Science ®Google Scholar
• Respondek G, Grimm M-J, Piot I, et al. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord. 2020;35(1):171–176.
   PubMedGoogle Scholar
• Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496–503.
   PubMed Web of Science ®Google Scholar
• Damron L, Bayram E, McGehrin K, et al. Physician-assisted dying: access and utilization in patients with movement disorders. Mov Disord. 2022;37(4):694–698.
   PubMedGoogle Scholar
• Pandit R, Chen L, Götz J. The blood-brain barrier: physiology and strategies for drug delivery. Adv Drug Deliv Rev. 2020;165-166:1–14.
   PubMed Web of Science ®Google Scholar
• Zeissler ML, Li V, Parmar MKB, et al. Is it possible to conduct a multi-arm multi-stage platform trial in Parkinson’s disease: lessons learned from other neurodegenerative disorders and cancer. J Parkinsons Dis. Internet. 2020;10(2): 413–428.
   PubMedGoogle Scholar
• Wills A, Pantelyat A, Espay A, et al. A modified progressive supranuclear palsy rating scale for virtual assessments. Mov Disord 2022;37(4):694–698.
   PubMedGoogle Scholar